nirmatrelvir/ritonavir vs triazolam
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of nirmatrelvir/ritonavir and triazolam. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
major Known Drug Interaction
Sedative/hypnotics triazolam, oral midazolam ↑ triazolam ↑ midazolam Co-administration contraindicated due to potential for extreme sedation and respiratory depression [see Contraindications (4) ] .
Paxlovid
Halcion
Paxlovid is a medicine used to treat mild to moderate COVID-19 in adults. It helps prevent severe illness, hospitalization, or death in people at high risk.
Triazolam (Halcion) is a medication used for the short-term treatment of insomnia. It belongs to a class of drugs called benzodiazepines, which help you fall asleep.
Paxlovid treats mild to moderate COVID-19 in adults. You must be at high risk of your illness becoming severe. This includes needing to go to the hospital or possibly dying from COVID-19. Paxlovid is not for preventing COVID-19 before or after exposure.
Triazolam is used to treat insomnia in adults. Insomnia is when you have trouble falling asleep or staying asleep. This medicine is only for short-term use, usually for 7 to 10 days.
Paxlovid contains two medicines, nirmatrelvir and ritonavir. Nirmatrelvir stops the virus from multiplying in your body. Ritonavir helps nirmatrelvir stay in your body longer so it can work better.
Triazolam works by slowing down activity in the brain. This helps you to relax and fall asleep. It affects certain chemicals in your brain called neurotransmitters.
- • Change in taste
- • Diarrhea
- • Drowsiness
- • Headache
- • Dizziness
- • Nervousness
- • Light-headedness
- COVID-19 22,774
- COVID-19 coming back 20,089
- Change in taste 7,316
- Diarrhea 4,003
- Feeling sick to your stomach 2,620
- Drug Abuse 519
- Sopor 402
- Nausea 352
- Overdose 350
- Fall 315
Paxlovid can interact with many other medicines, causing serious or life-threatening problems. Before taking Paxlovid, tell your doctor about all the medicines you take. Your doctor may need to adjust the dose of your other medicines or monitor you more closely.
Taking triazolam with opioid pain medicines can cause very serious problems, including slowed or stopped breathing, coma, and death. Because of these risks, doctors will only prescribe opioid pain medicines with triazolam when other treatment options are not sufficient. Do not misuse this medicine. Misuse can lead to addiction, overdose, or death. Stopping triazolam suddenly can cause dangerous withdrawal symptoms. Talk to your doctor before stopping this medicine.
There is not enough information about nirmatrelvir's safety during pregnancy. Studies on ritonavir in pregnant women have not shown an increased risk of birth defects. Talk to your doctor about the risks and benefits of taking Paxlovid if you are pregnant or breastfeeding.
Taking triazolam late in pregnancy may cause sedation or withdrawal symptoms in the newborn. If you are pregnant or plan to become pregnant, talk to your doctor about the risks and benefits of taking triazolam. A registry exists to track outcomes in women who take psychiatric medications, including triazolam, during pregnancy.
Also Compare, Nearby Drugs
Compare triazolam with
How to Read This nirmatrelvir/ritonavir vs triazolam Comparison
nirmatrelvir/ritonavir is classified in the Antiviral (Protease Inhibitor Combination) drug class, while triazolam sits within the Benzodiazepine (Hypnotic) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, nirmatrelvir/ritonavir has 56,802 submissions while triazolam has 1,938. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known major interaction flagged in FDA labeling, attributed to nirmatrelvir/ritonavir prevents your body from breaking down triazolam, leading to much higher levels of the sedative in your blood. this can cause you to become dangerously sleepy or have trouble breathing.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for nirmatrelvir/ritonavir or triazolam.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.